In patients with psoriasis, biologics may reduce ocular surface and corneal inflammation — especially dry eye, conjunctivitis ...

Conclusions: With the development of recombinant DNA techniques, it has become possible to develop new biologic therapies that can be designed to specifically alter physiological responses. These new ...

Interleukin-23 inhibitors, prior treatment history, and Psoriasis Area and Severity Index scores may be predictive of time to disease relapse among patients with psoriasis who achieved clinical ...

Researchers identified multiple gene signatures linked to psoriasis severity, body weight, and immune activity. These ...

The course of COVID-19 in patients with psoriasis was characterized and factors associated with hospitalization were identified in an international case study. The use of biologic agents among ...

Please provide your email address to receive an email when new articles are posted on . This study compared risankizumab with other biologics in both biologic-naïve and biologic-experienced patients.

Please provide your email address to receive an email when new articles are posted on . The majority of patients and clinicians agreed with the use of as-needed biologic therapy for psoriasis.

Psoriasis is a common inflammatory skin disease linked to several long-term health conditions, such as heart disease, ...

Higher BMI, BMR, BSA, and weight correlate with more severe psoriasis and reduced treatment efficacy, particularly with biologic therapies. Personalized dosing strategies may be necessary for biologic ...

Some 25% of patients with psoriasis eventually develop psoriatic arthritis, but the risk may be mitigated with targeted therapies. This single-center study found that progression to PsA was more ...

For patients with plaque psoriasis who initiated treatment with a first-line biologic, the average treatment cost more than doubled from 2007 to 2021 as more patients started newer IL-17 and IL-23 ...

The psoriasis market is experiencing steady growth, driven by rising disease prevalence, improved diagnosis rates, and greater patient access to advanced therapies. The shift from conventional ...